Sign In
VXRT.US
id: 351
It is still possible to file a late claim. The court will decide whether to accept late claims or not.
N.D. California
Court
15 Jun 2020
Class period Start
19 Aug 2020
Class period End
31 Jan 2023
Claim deadline
In re VAXART, INC. SECURITIES LITIGATION.

Vaxart Inc. (VXRT) agreed to pay $12 million to settle a securities class action lawsuit.

The complaint alleged a fraudulent scheme to profit from artificially inflating the Company’s stock price by announcing false and misleading information concerning Vaxart’s oral COVID-19 vaccine candidate.

Specifically, the Complaint alleged that on June 26, 2020, Vaxart issued a press release entitled, “Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed,” falsely claiming its vaccine had been selected to participate in a non-human challenge study, organized and funded by OWS.

The Complaint alleged that on July 25, 2020, details emerged revealing the Company and its Leaders' deception concerning their alleged pump and dump scheme. In particular, on July 25, 2020, The New York Times published an article entitled, “Corporate Insiders Pocket $1 Billion in Rush for Coronavirus Vaccine,” covering suspiciously timed stock bets that had generated significant profits for senior executives and board members at companies developing vaccines and treatments. Vaxart was featured prominently in the article, and it clarified “Vaxart is not among the companies selected to receive significant financial support from Warp Speed.”

Vaxart (VXRT) agreed to settle with investors to avoid further litigation.
Case Status
Accepting Late Claims
Alleged Offence
Other
Suspected Party
Other
Security Type
Stocks
Trade Direction
Long
Plaintiffs
Wei Huang, Langdon Elliot, Ani Hovhannisyan
Attorneys
Hagens Berman Sobol Shapiro LLP, Scott + Scott Attorneys
Judge
Hon. Vince Chhabria
Administrator
A.B. Data Ltd
Court hearing date
12 January 2023
Trades matching type
FIFO
+$12,015,000
Cash Settlement Amount

Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline include...

    Ticker
    VXRT.US
    ISIN
    US92243A2006
    CIK
    72444
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    170 Harbor Way, South San Francisco, CA, United States, 94080